FARONEX

Faropenem

COMPOSITION

FARONEX 150 Tablet: Each film coated tablet contains Faropenem Sodium Hydrate JP equivalent to Faropenem 150 mg.
FARONEX 200 Tablet: Each film coated tablet contains Faropenem Sodium Hydrate JP equivalent to Faropenem 200 mg.

PHARMACOLOGY

Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It has broad-spectrum antibacterial activity against many gram-positive and gram-negative aerobes and anaerobes. Compared with imipenem, it has improved chemical stability. It has reduced central nervous system effects. In addition, it is resistant to hydrolysis by beta-lactamases.

INDICATION

- Urinary tract infections: (e.g., pyelonephritis, cystitis, prostatitis, seminal gland inflammation).
- Lower respiratory tract infections: (e.g., acute bronchitis, pneumonia, pulmonary suppuration).
- Upper respiratory tract infections: (e.g., pharyngitis, tonsillitis).
- Skin and skin structure infections: (e.g., pustular acne, folliculitis, contagious impetigo, erysipelas, lymphangitis, suppurative nail inflammation, subcutaneous abscess, hidradenitis (sweat gland inflammation), infective sebaceous cyst, chronic pyoderma, secondary infection of external wounds or surgical wounds).
- Ear, nose and throat (ENT) infections: (e.g., otitis externa, tympanitis, sinusitis).

DOSAGE AND ADMINISTRATION

Indication	Dosage
Urinary tract infections	200 mg three times daily dose can be increased to 300 mg.
Lower respiratory tract infections	200 mg three times daily dose can be increased to 300 mg.
Upper respiratory tract infections	150 mg three times daily dose can be increased to 200 mg.
Skin and skin structure infections	150 mg three times daily dose can be increased to 200 mg.
ENT infections	200 mg three times daily dose can be increased to 300 mg.

The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings.

CONTRAINDICATION

It is contraindicated in patients with known hypersensitivity to any of the components of this product or to other drugs in the same class, or in patients who have demonstrated anaphylactic reactions to beta-lactams.

WARNING & PRECAUTION

It should be administered with caution in the following:

- Patients with a history of hypersensitivity to penicillin, cephem or carbapenem drugs.
- Patients with a family history of atopy.
- Patients with renal impairment. In these patients the dosage should be reduced or the interval between doses should be increased.
- Geriatric patients.
- Patients with poor oral intake or poor general state (since there are cases that show symptoms of vitamin K deficiency, proper monitoring should be done).

SIDE EFFECT

It is generally well tolerated. The most frequently reported side effects are diarrhoea, abdominal pain, loose bowel movements, nausea and rash.

USE IN PREGNANCY & LACTATION

Safety during pregnancy has not been established. Faropenem is excreted in human milk. Therefore, it should be given to them only if the benefits outweigh the risks.

USE IN CHILDREN AND ADOLESCENTS

Safety in infants has not been established.

DRUG INTERACTION

- Imipenem and Cilastatin Sodium combination: It has been reported that in animal studies (rat), the concentration of the drug in the blood increases.
- Furosemide: Reported in animal studies (dog), that the kidney toxicity of the drug increases.
- Sodium valproate: The concentration of valproic acid in the blood reduces, and there is a recurrence of epileptic fits.

OVERDOSAGE

No specific information is available on the treatment of overdosage with Faropenem. In the event of an overdose, Faropenem should be discontinued, and general supportive treatment given until renal elimination takes place.

STORAGE

Store below 25°C temperature in a cool and dry place. Protect from light & moisture. Keep out of the reach of children.

HOW SUPPLIED

FARONEX 150 Tablet: Each box contains 12 tablets in Alu-Alu blister pack.
FARONEX 200 Tablet: Each box contains 12 tablets in Alu-Alu blister pack.

Manufactured by:
NIPRO JMI Pharma Ltd.
Chauddagram, Cumilla, Bangladesh.

NIPRO JMI Pharma

14020000404/00